Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer
Tumor mutation burden (TMB) serves as an effective biomarker predicting efficacy of mono-immunotherapy for non-small cell lung cancer (NSCLC). Establishing a precise TMB predicting model is essential to select which populations are likely to respond to immunotherapy or prognosis and to maximize the...
Main Authors: | Yuan Qiu, Liping Liu, Haihong Yang, Hanzhang Chen, Qiuhua Deng, Dakai Xiao, Yongping Lin, Changbin Zhu, Weiwei Li, Di Shao, Wenxi Jiang, Kui Wu, Jianxing He |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.608989/full |
Similar Items
-
Intratumor heterogeneity of driver mutations and TMB distribution in 30 early-stage LUAD patients with multiple lesions
by: Yuan Qiu, et al.
Published: (2022-08-01) -
Correlation between Pre-treatment Anemia and Prognosis in Non-small Cell Lung Cancer Patients
by: Qiuhua DENG, et al.
Published: (2010-07-01) -
Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD
by: Dakai Xiao, et al.
Published: (2017-05-01) -
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
by: Yaxiong Zhang, et al.
Published: (2019-04-01) -
The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Giovanni Maria Iannantuono, et al.
Published: (2022-08-01)